Slide

Central Nervous System Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-102 SL   Acute Stress Disorder
First patient enrolled in investigator-initiated Phase 2 in May 2025

Phase II

TNX-102 SL   Major Depressive Disorder
Phase II Ready

Phase II Ready

Immunology Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-1500   Organ Transplant Rejection / Autoimmune Disorders
Phase I  — Clinical phase complete

Preclinical

TNX-1700   Gastric and Colorectal Cancer
Preclinical

Preclinical

Infectious Disease Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-801   Smallpox and Monkeypox Preventing Vaccine
Preclinical

Preclinical

TNX-4200   CD45
Preclinical

Preclinical

Rare Disease Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-2900   Prader-Willi Syndrome
Phase II ready – FDA Orphan Drug and Rare Pediatric Disease Designation

Phase II Ready